Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of NVP-1705 vs NVP-1705-R in Healthy Subjects
NCT05141110Phase 1Completed
- Sponsor
- NVP Healthcare Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NVP-1705 in hypertension (HTN) (2 arms), sponsored by NVP Healthcare Co., Ltd. Primary endpoints: Area under the plasma drug concentration-time curve (0-48h) and Maximum observed plasma concentration. Started Dec 2021; status: completed.
02
Drugs
NVP-1705
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05141110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141110.